1. Scrip
  2. >>R&D
  3. >>Clinical Trials

AZ Hopes Coupling GLP-1 Bydureon and SGLT-2 Forxiga Is Paradigm Shift

 
• By Sten Stovall

AstraZeneca hopes positive results from its DURATION-8 trial combining its GLP-1 drug Bydureon and SGLT2 product Forxiga for the first time will spur use – and sales – for each, and open the way for an additional line of defense for type 2 diabetes patients before they are moved onto insulin.

SC1609_Diabetes Type 2_1200x675

Results of AstraZeneca PLC’s late-stage study dubbed DURATION-8 is the first trial to evaluate the combination of the two diabetes treatments Bydureon (GLP-1) and Forxiga (SGLT-2) and confirmed what many experts had presumed - that they work better together than separately at reducing blood sugar in patients whose diabetes couldn’t be controlled with first-line therapy metformin, potentially opening a new treatment approach.

The study, released at this year’s annual meeting of the European Association for the Study of Diabetes (EASD) in Munich, Germany and simultaneously published in The Lancet Diabetes & Endocrinology, hit all primary endpoints, reducing blood sugar, weight and systolic blood pressure in patients with type 2 diabetes, versus each medicine on their own, and showed cardiovascular risk benefit

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from R&D